Silver Book Fact

Catheter ablation reduces risk of stroke and death among AFib patients

Atrial fibrillation patients who underwent catheter ablation had a reduced risk of stroke and death—2.2% of those who had ablation experienced stroke versus 4.7% on medications alone, and 6% died from stroke versus 23.5% of those on medications alone.

Day, JD, BG Crandall, JS Osborn, JP Weiss, DL Lappe, T Bair, H May, JL Anderson, B Muhlestein, J Nelson, and TJ Bunch. Atrial Fibrillation Ablation Significantly Reduces Long-Term Mortality and Strokes in a Large Patient Population; 2010

Reference

Title
Atrial Fibrillation Ablation Significantly Reduces Long-Term Mortality and Strokes in a Large Patient Population
Publication
Heart Rhythm Society 2010 Scientific Sessions
Publication Date
2010
Authors
Day, JD, BG Crandall, JS Osborn, JP Weiss, DL Lappe, T Bair, H May, JL Anderson, B Muhlestein, J Nelson, and TJ Bunch

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Stroke prevention through optimal anticoagulation
    If half of atrial fibrillation patients who currently receive warfarin in a routine care setting had their anti-coagulation optimized, around 9,000 strokes and more than 29,000 bleeds would be prevented.  
  • t-PA cost savings
    The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means…  
  • Identifying individuals at high risk for developing AFib
    Using simple bedside measures, identification of individuals at risk for developing atrial fibrillation is feasible. Selecting high-risk individuals for inclusion in atrial fibrillation prevention trials may also enhance prevention strategies.  
  • Cost-savings associated with optimal anticoagulation in AFib patients
    If half of all atrial fibrillation patients receiving suboptimal or no anticoagulation instead received optimal anticoagulation, 28,000 strokes could be prevented each year at a savings of around $2.5 billion in direct…  
  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.